Incannex Healthcare vs Silo Pharma
IXHL and SILO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IXHL and SILO compare
Incannex Healthcare is the larger company, worth 8.0 times as much as Silo Pharma ($21.8M against $2.7M).
Incannex Healthcare scores higher on the StockData Score (7 against 2 for Silo Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IXHL | SILO |
|---|---|---|
| Size and price | ||
| Market cap | $21.8M | $2.7M |
| Share price | $1.74 | $1.71 |
| Change, 1 year | −83.5% | −72.4% |
| Change, 5 years | – | −98.8% |
| Beta (5Y) | 2.40 | 2.90 |
| Employees | 12 | 3 |
| StockData Score | ||
| Total score | 7 (better) | 2 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 50.2× |
| P/B | 0.3× (better) | 0.6× |
| FCF yield | −14.6% | – |
| Growth | ||
| Revenue growth (TTM) | – | −25.0% |
| Revenue growth, 5Y average | – | 12.0% |
| Profitability | ||
| Gross margin | – | −14.8% |
| Operating margin | – | −8250% |
| Net margin | – | −8270% |
| Return on equity | −20.7% (better) | −91.2% |
| Return on invested capital | −1945% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −112.0× |
| Current ratio | 67.79 (better) | 5.36 |
| Altman Z-score | −0.22 (better) | −5.17 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −42.2% | – |
| Shareholder yield | −42.2% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 3.6% | 9.0% |
| Held by insiders | – | 13.8% |
| Insider net buying, 12 months | – | $2.1K |
| Short interest, % of float | – | 1.0% |
Go deeper
- IXHL stock overview
- IXHL income statement
- IXHL valuation and score
- SILO stock overview
- SILO income statement
- SILO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.